LANGHORNE, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will be presenting at the Planet MicroCap Showcase: Vegas 2025, taking place at the Paris Hotel & Casino, Las Vegas, NV on April 22-24,... Read more
RA'ANANA, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced the successful completion of the first human treatment using its U.S. Food and Drug Administration-cleared INSPIRA™ ART100 system in a critical life-support procedure.
The procedure was successfully performed by expert physicians at Westchester... Read more
Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology
Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash., April 7, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the... Read more
New devices address infusion delivery variability and expand the ICU Medical IV Performance Platform. SAN CLEMENTE, Calif., April 7, 2025 /PRNewswire/ -- ICU Medical Inc. (NASDAQ:ICUI), a worldwide leader in the development, manufacture and sale of innovative medical devices, has announced 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Plum Solo™ precision IV pump, a single-channel complement to the dual-channel Plum Duo™.... Read more
New Diabetes Canada Guidelines1 recommend people with type 1 diabetes use an Automated Insulin Delivery System (AID) System for diabetes management
Approximately 300,000 Canadians have type 1 diabetes, with the number of cases growing at an estimated 4.4% per year2
The Omnipod 5 System is designed to be customer-centric and aims to deliver exceptional ease of use. It has demonstrated strong clinical results including lower A1c and improved time in range, while... Read more
Patient Diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ Treated Once with Light-Activated Ruvidar(TM) Demonstrates 7 Year Complete Response Toronto, Ontario--(Newsfile Corp. - April 7, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small... Read more
Novel hybrid LTS-HTS superconducting magnet enables high-resolution for liquids and solids ultra-high field NMR research in biomolecular and advanced materials sciences ASILOMAR, Calif. / Apr 07, 2025 / Business Wire / At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the successful development and testing of the world’s first high-resolution 1.3 GHz NMR spectrometer... Read more
Unique Fourier 80 ‘Multi-Talent’ offers 1H NMR and choice of 15 X-nuclei with just one click ASILOMAR, Calif. / Apr 07, 2025 / Business Wire / At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the launch of an innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer, known as the ‘Multi-Talent’ configuration. This novel Fourier 80 ‘Multi-Talent’ system... Read more
PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace, as the Chairman of the Board to... Read more
Sea's pre-clinical stage neurotherapeutic synthetic oral molecules act at the neurotransmitter glutamate pathway on two clinically validated targets in the CNS (central nervous system) Sea's lead molecule SPM-0404 is a potential new oral treatment in investigational new drug (IND)-enabling studies for constant bothersome tinnitus, epilepsy, and sporadic ALS (S-ALS) Pre-clinical development work by Inotiv, Inc. to support Sea filing IND application at FDA... Read more
Q1 2025 preliminary net sales rise 7% CER and adjusted diluted EPS results of at least $0.55 CER both above outlook despite challenging macro environment Full-year 2025 adjusted diluted EPS outlook raised to about $2.35 CER (prior outlook about $2.28 CER) On track to exceed 31% CER adjusted operating income margin ahead of 2028 mid-term target VENLO, Netherlands / Apr 06, 2025 / Business Wire / QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced... Read more
Toronto, Ontario--(Newsfile Corp. - April 4, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Farlinger has joined the Company's Board of Directors. Mr. Farlinger will also serve as Chair of the Company's audit committee.
Mr. Farlinger is a veteran venture and private equity... Read more
VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the U.S. commercial launch of Cohealyx™, a collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. Cohealyx is designed to facilitate cellular migration and revascularization, thereby providing an ideal wound bed for definitive closure.... Read more
New Prague, Minnesota--(Newsfile Corp. - April 3, 2025) - Electromed, Inc. (NYSE American: ELMD) announced today that it will be participating in the 15th Annual LD Micro Invitational at the Westin Grand Central in New York on April 9th and 10th, 2025.
Electromed, Inc. is scheduled to present on April 10, 2025 at 02:30 PM. Jim Cunniff, President and Chief Executive Officer, will be representing the company.
Interested parties may register to access the live webcast of... Read more
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified, accurate, and efficient way to diagnose obstructive sleep apnea (OSA) from the comfort of an... Read more
THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO), being held April 13-16, 2025 in Rotterdam, Nether... Read more
MOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending and presenting at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held in San Diego from April 5 – 9. This includes an oral presentation on data from the Post-Approval Study (PAS) of the RNS® System in adults treated with brain-responsive... Read more
Data Also Highlights Continued Clinical Advances Using the CyberKnife System That are Making
High Quality Care an Option for People Who Previously Had Limited Choices MADISON, Wis., April 3, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data on the clinical use of the CyberKnife® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors. Malignant brain and other CNS tumors... Read more
With the addition of the Pounce™ XL Thrombectomy System, indicated for use in 5.5–10 mm peripheral arteries, the fully mechanical Pounce™ Thrombectomy Platform can now remove thrombi or emboli throughout the lower and upper extremities without aspiration, thrombolysis, or capital equipment EDEN PRAIRIE, Minn. / Apr 03, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care... Read more
Consistent with prior studies, published results from Castle’s DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity, who can safely consider forgoing the sentinel lymph node biopsy (SLNB) surgical procedure, and who are also unlikely to experience disease progression1,2
As of the last follow-up, all of the patients in the third study analysis with a low-risk DecisionDx-Melanoma test... Read more
EDEN PRAIRIE, Minn., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock.
All of the shares of common stock to be sold in the proposed offering will be sold... Read more
ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time.
Preliminary First Quarter 2025 Resul... Read more
Introduction of EluPro at Heart Rhythm 2025 in San Diego, April 25-27, 2025 SILVER SPRING, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, is proud to announce the debut of its EluPro™ Antibiotic-Eluting BioEnvelope designed for cardiac implantable electronic devices (CIEDs) and neurostimulators at the Heart Rhythm Society’s annual meeting (HRS 2025).... Read more
ALAMEDA, Calif., April 2, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The data showed that CAVT as a frontline therapy for blood clots not only improved clinical and functional outcomes but can also help reduce overall healthcare costs. "With... Read more
IRVINE, Calif. / Apr 02, 2025 / Business Wire / Masimo (NASDAQ: MASI) today announced that its management will participate in the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 2:15 p.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company... Read more
HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has successfully enrolled the first patients in its clinical trial at the University of California, San Diego (UCSD), in collaboration with the VA San Diego Healthcare System (San Diego VA). The company began treatment of the first patients... Read more
Clareon PanOptix Pro provides unprecedented 94% light utilization, resulting in half the light scatter of Clareon PanOptix1,2,§,*
Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast1,†
Commercially available in the U.S. in May, Clareon PanOptix Pro is the next generation of the world’s leading trifocal IOL3-5,‡ GENEVA / Apr 02, 2025 / Business Wire / Alcon (SIX/NYSE: ALC),... Read more
FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases WALTHAM, Mass. / Apr 02, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining... Read more
Akoya’s technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative
The unprecedented scale of the initiative requires the high plex and high throughput of Akoya’s PhenoCycler-Fusion platform to process thousands of patients' samples MARLBOROUGH, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, and... Read more
CARLSBAD, California, April 02, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the publication of a new clinical study titled "Fixation of the Sacroiliac Joint: A Cadaver-Based Concurrent-Controlled Biomechanical Comparison of Posterior Interposition and Posterolateral Transosseous Techniques" in... Read more
Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to screening by enabling discreet self-collection
Quest also plans to make self-collection option available at its 2,000 patient service centers in the United States early next month, expanding access to screening
New solution follows company's launch of GTI self-collection option... Read more
First successful customer installation of novel dissolution d-DNP Polarizer at UCSF SAN FRANCISCO / Apr 02, 2025 / Business Wire / Bruker Corporation today announced the introduction of its groundbreaking dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer at the 2025 Hyperpolarized Carbon-13 MRI Technology Development Workshop at the University of California San Francisco (UCSF) Hyperpolarized MRI Technology Resource Center. The first customer installation of... Read more
Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C., April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease. The new test... Read more
LATHAM, N.Y. / Apr 02, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025.
Fiscal Year 2025 Third Quarter Highlights Quarter Ended... Read more
Two posters will share data on the significant risk stratification provided by DecisionDx-Melanoma in a real-world cohort of patients with stage IIB-IIC cutaneous melanoma (CM) to help guide adjuvant therapy, and the role of the test in prompting use of imaging surveillance in early-stage patients at high risk of metastasis to the central nervous system (CNS) FRIENDSWOOD, Texas, April 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving... Read more
BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:45 PM EDT.
About LeMaitre
LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable... Read more
Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), its wholly-owned clinical laboratory subsidiary, is repositioning its TR8™ PGx pharmacogenomics testing service to offer tailored subpanels... Read more
ROSELAND, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that InfiniSurg, LLC, a premier ambulatory surgery center based in New Jersey, has incorporated the CompuFlo® Epidural System into its clinical practice. The device will be utilized by Roman Kosiborod, DO, a highly experienced anesthesiologist and pain management... Read more
BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer’s disease, and a subsidiary of Beyond Air (NASDAQ: XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in Translational Psychiatry, a peer-reviewed medical journal published... Read more
BURNABY, British Columbia / Apr 01, 2025 / Business Wire / As of today, the Government of Saskatchewan’s expanded public coverage for continuous glucose monitoring (CGM) systems comes into effect. Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, applauds this decision as a testament to the government’s commitment to improving diabetes care. The expansion, which now provides full coverage for continuous... Read more
News Summary Boosts out-of-the-box sensitivity by up to 80 times with MaxPeakTM Premier columns.1
Delivers over threefold improvements in day-to-day reproducibility2 and decreases carryover by up to two orders of magnitude.3
Reduces common user errors by up to 40%.4 MILFORD, Mass., April 1, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the expansion of the Alliance™ iS Bio HPLC product line with integrated photodiode array (PDA) detection,... Read more
Expanding Thoracic Portfolio WARSAW, Ind., and ZUG, Switzerland, April 1, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today announced its RibFix Advantage® Fixation System has received CE Mark certification – the first CE Mark for an intrathoracic rib fixation system.
The RibFix Advantage Fixation System is intended for the thoracoscopic fixation, stabilization and fusion of rib fractures1,... Read more
WAYNE, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced FDA 510(k) clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP). Leveraging the patented technology of the AC3 Optimus™ IABP, the AC3 Range™ IABP is designed to provide reliable, ongoing IABP support across various patient transport modes, including ambulances and both fixed- and rotary-wing aircrafts.
The AC3... Read more
The Company Reaffirms Full Year 2025 Guidance: Revenue Growth of 8-10% and Adjusted EBITDA (non-GAAP) margin greater than 18.8% ROCHESTER HILLS, Mich. / Apr 01, 2025 / Business Wire / InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that Richard DiIorio will be stepping... Read more
Malaria remains a major global health threat, with more than 250 million cases and 600,000 deaths in 2024 – over 90% of them in Africa
QIAprep& Plasmodium Kit enables streamlined detection of five malaria-causing parasites for epidemiological research and surveillance
Novel QIAGEN assays support mixed-infection tracking, vaccine impact assessment and malaria control strategies in regions with limited healthcare infrastructure VENLO, Netherlands / Apr 01, 2025... Read more
FT. MYERS, Fla. / Apr 01, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading oncology testing services company, today announced that Tony Zook has officially assumed the role of Chief Executive Officer. A member of the company’s Board of Directors since 2023, Zook brings more than three decades of experience across diagnostics and biopharma, along with a proven track record of leadership in healthcare.
“Tony has... Read more
Simoa® technology highlighted in more than 80 posters and oral presentations demonstrating its impact on neurodegenerative disease research BILLERICA, Mass. / Apr 01, 2025 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the inclusion of a new dried blood spot extraction (DBS) kit as part of their industry-leading Simoa® assay kits at the International Conference... Read more
PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended December 31, 2024, and provided a corporate update. The Company reported a... Read more
Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe
Operating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focus
Strategic partnerships with industry leaders mark key progress
Company highlights its early accomplishments for 2025 BERKELEY, Calif. and MAINZ, Germany, April 01, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or... Read more
BURLINGTON, Mass. / Mar 31, 2025 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, president and chief executive officer and David Henry, chief financial officer, will present at the 24th Annual Needham Virtual Healthcare Conference, being held from April 7th... Read more
